Aakaar Medical Technologies Limited approved the ESOP 2026 Scheme and increased its authorised share capital to ₹15.40 crore during its 13th Annual General Meeting held on June 30, 2026. The meeting, conducted via video conferencing, also saw the re-appointment of Mr. Dilip Meswani as Director and the appointment of a secretarial auditor for a period of five years commencing from FY2026-27. These decisions are aimed at supporting employee compensation and providing flexibility for future capital requirements.

The Board's performance during FY2025-26 was reviewed, with no qualifications or adverse remarks reported by the statutory or secretarial auditors. Mr. Dilip Meswani, Founder & Managing Director, provided a detailed update on the company's performance, new product introductions, and growth prospects for the financial year. Mrs. Bindi Meswani, Chairman, addressed the macro-economic environment and its impact on the company's operations.

Shareholders passed five resolutions through remote e-voting, including the adoption of audited financial statements for the financial year ended March 31, 2026. The alteration of the capital clause in the Memorandum of Association was approved to facilitate the increase in authorised share capital. The authorised share capital is now ₹15,40,00,000 divided into 1,54,00,000 equity shares of ₹10 each.

Resolutions Passed at the 13th AGM

Meeting Details

The meeting commenced at 3:00 p.m. IST and concluded at 3:18 p.m. IST. Mr. Anoopkumar Pillai, Company Secretary & Compliance Officer, confirmed that the meeting was held in compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The e-voting facility was available until 5:00 p.m. on June 30, 2026. The scrutinizers' report regarding the voting results will be disseminated to the National Stock Exchange and made available on the company's website within 48 hours of the meeting's conclusion.

Aakaar Medical Technologies Limited reported a financial performance for FY26 with revenue reaching ₹66.9 crore, up from ₹61.6 crore in the previous year. The company maintained its profitability streak with a Profit After Tax (PAT) of ₹6.6 crore compared to ₹6.0 crore in FY25. EBITDA for the period was recorded at ₹10.97 crore, reflecting an EBITDA margin of 16.39%.

The company operates through comprehensive business segments focusing on aesthetics products, devices, and device consumables. Aesthetics products and device consumables constitute the majority of the revenue, contributing to a recurring business model. The gross profit for FY26 was ₹39.5 crore with a margin of 59.34%.

Financial Performance

The statement of profit and loss highlights steady growth across key metrics. Total income for FY26 stood at ₹67.7 crore. Employee benefits expense increased to ₹14.0 crore, and other expenses were recorded at ₹14.5 crore. Finance costs for the year amounted to ₹1.6 crore.

Balance Sheet Overview

The balance sheet size expanded to ₹79.4 crore in FY26 from ₹54.2 crore in FY25. Shareholders' funds saw significant growth, with share capital rising to ₹14.2 crore and reserves and surplus reaching ₹40.3 crore. Trade receivables increased to ₹37.22 crore, while the cash and bank balance grew substantially to ₹16.2 crore.

Business Segments and Growth

Aakaar Medical Technologies offers a diversified portfolio including injectables, contouring, professional skincare, and homecare solutions. The company manages 146 brands and serves over 5,000 doctors through its distribution network. The strategy emphasizes a product-led, recurring annuity-based business model with a focus on expanding its stockist network.